Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of AL8326 in relapsed or progressive small cell lung cancer after at least second-line therapy
CTR20233349Phase 3Active
- Sponsor
- Adcentrx Therapeutics
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing AL8326 with Placebo (2 arms). Primary endpoint: Overall survival. Started Dec 2023; status: active.
02
Drugs
AL8326
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20233349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233349.